Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Plasma levels of beta-amy… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins.

Artikel i vetenskaplig tidskrift
Författare Kina Höglund
Olov Wiklund
Hugo Vanderstichele
Oliver Eikenberg
Eugeen Vanmechelen
Kaj Blennow
Publicerad i Archives of neurology
Volym 61
Nummer/häfte 3
Sidor 333-7
ISSN 0003-9942
Publiceringsår 2004
Publicerad vid Wallenberglaboratoriet
Institutionen för klinisk neurovetenskap, Sektionen för laborativ neurovetenskap
Sidor 333-7
Språk en
Länkar dx.doi.org/10.1001/archneur.61.3.33...
Ämnesord Adult, Aged, Amyloid beta-Protein, blood, Anticholesteremic Agents, therapeutic use, Cross-Over Studies, Dose-Response Relationship, Drug, Enzyme-Linked Immunosorbent Assay, methods, Female, Heptanoic Acids, therapeutic use, Humans, Hypercholesterolemia, blood, drug therapy, Lipids, blood, Male, Middle Aged, Peptide Fragments, blood, Prospective Studies, Pyrroles, therapeutic use, Simvastatin, therapeutic use, Time Factors
Ämneskategorier Psykiatri

Sammanfattning

BACKGROUND: Epidemiological studies suggest that statins reduce the risk of developing Alzheimer disease. Cell and animal experiments have revealed a connection between cholesterol metabolism and the processing of amyloid precursor protein. To our knowledge, the mechanism for statins in risk reduction of Alzheimer disease is unknown. OBJECTIVE: To test the effect of statin treatment on beta-amyloid (A beta) metabolism in humans. DESIGN: A prospective, randomized, dose-finding 36-week treatment trial with statins. Plasma samples were taken at baseline (week 0) and at weeks 6, 12, and 36. SETTING: Outpatient clinical study at a university hospital. PATIENTS: Thirty-nine patients who met the criteria for hypercholesterolemia. INTERVENTIONS: Patients were randomized to oral treatment with either simvastatin or atorvastatin calcium according to the following regimen: simvastatin, 40 mg/d, or atorvastatin, 20 mg/d, for 6 weeks; followed by simvastatin, 80 mg/d, or atorvastatin, 40 mg/d, for 6 weeks; and finally, simvastatin, 80 mg/d, or atorvastatin, 80 mg/d, for 24 weeks. MAIN OUTCOME MEASURES: Plasma levels of A beta(1-40) and A beta(1-42) were measured using 2 enzyme-linked immunosorbent assays, and total A beta was quantified by Western blotting. RESULTS: Treatment with both statins reduced total plasma cholesterol levels by 56% (P =.00). The plasma levels of A beta(1-40), A beta(1-42), and total A beta were stable in individual patients during the treatment period. No significant change in the level of A beta(1-40), A beta(1-42), or total A beta was found. CONCLUSION: This study questions the effect of statins on the processing of amyloid precursor protein in humans.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?

Denna text är utskriven från följande webbsida:
http://www.gu.se/forskning/publikation/?publicationId=99225
Utskriftsdatum: 2020-07-05